Monoclonal Antibodies Market Size By Type (Fully Human, Humanized, Chimeric), By Application (Oncology, Autoimmune Diseases, Infectious Diseases), By End-use (Hospitals, Specialty Centers), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 - 2028

Industry Overview

Monoclonal Antibodies Market size crossed USD 180.5 billion in 2021 and is expected to witness a CAGR of 12.9% from 2022 to 2028 driven by the rapid growth in the prevalence of chronic infectious and rare diseases.
 

Get more details on this report - Request Free Sample PDF
 

For instance, according to the World Health Organization, in 2020, around 10 million people died due to cancer worldwide. This has proportionated one third deaths due to cancer in respective year. Therefore, increasing need for effective and affordable therapies for cancer treatment will boost the monoclonal antibodies market growth.
 

Additionally, significant number of monoclonal antibodies are indicated for cancer treatment therapies that has offered revenue growth opportunities to the market. Thus, increasing product adoption to reduce disease-associated mortality rate will excel the industry growth during projection period. Moreover, extensive product pipeline with potential effective therapies catering to such diverse range of diseases will result in market expansion. Thus, with high product approval rate, contributing to increasing accessibility, the market will witness significant revenue growth during forecast timeframe.
 

The COVID-19 virus outbreak has positively influenced the monoclonal antibodies market growth. Sudden upsurge in number of patients associated with COVID-19 and mortality risk associated with the infection have driven the need for effective therapies. Adding to this, several industry players are continuously involved in development of innovative monoclonal antibodies for prevention and treatment of COVID-19 virus due to its potential to combat disease burden.
 

Moreover, large number of ongoing clinical trials to develop novel drug therapy as well as wide range of product approvals for emergency use in COVID-19 treatment has propelled market growth during pandemic.
 

Monoclonal antibodies are referred to the category of proteins having ability to bind to specific cells. These are identical immunoglobulins derived from a single B-cell that recognizes unique binding site on antigen. Due to its specificity to unique epitopes, mAbs are being increasingly used for diagnostic and therapeutic applications for several disease. Currently, large number of monoclonal antibodies are available in the monoclonal antibodies market to treat cancer, cardiovascular diseases, autoimmune diseases, blood disorders, and infectious diseases among others.
 

Strong R&D activities for novel product development and extensive product launches will foster market expansion

Strong focus on discovery and development of novel monoclonal antibodies therapeutics to offer highly specific treatment to complex and severe diseases will stimulate monoclonal antibodies market growth potential. Government support and regulatory approvals to expand monoclonal antibodies market will majorly benefit industry players.
 

For instance, in June 2021, European Commission (EC) approved Bristol Myers Squibb’s combination therapy of OPDIVO and Yervoy to treat patients associated with malignant pleural mesothelioma. This will result in extension of product line availability in the market.  Similarly, in February 2020, Regeneron announced collaboration with The U.S. Department of Health and Human Services (HHS) to develop innovative monoclonal antibody therapeutics to provide treatment for the COVID-19 infection.
 

Greater specificity of human monoclonal antibody therapeutics for several disease treatments will spur product demand

Get more details on this report - Request Free Sample PDF
 

Monoclonal antibodies market based on type is classified into fully human, humanized, chimeric, and others. Fully human monoclonal antibodies segment dominated the monoclonal antibodies industry with more than 50% market share in 2021. Increase in number of product approvals and drug launches of fully human monoclonal antibodies has positively impacted the segment growth during estimated period.
 

Integration of advanced technologies has enabled faster discovery and product development. This will further lead to a shift in focus toward the use of human mAbs for immunotherapeutic applications. Hence, expanding applications of fully human monoclonal antibodies in immunology will continue to drive the segment growth in the forthcoming years. Moreover, several market players are focusing on the development of human monoclonal antibodies to treat COVID-19 patients. This will proliferate segmental growth during the forecast period.
 

High adoption of mAb therapies in cancer treatment will impel the industry landscape

Get more details on this report - Request Free Sample PDF
 

Monoclonal antibodies market by application is classified into oncology, autoimmune diseases, infectious diseases, and others. Oncology segment is anticipated to proceed at 13% CAGR through 2028. Monoclonal antibodies are proven effective for targeted treatment of cancer. Moreover, numerous monoclonal antibodies have multiple applications offering advantage of single mAb to target different types of cancers. Thus, increasing prevalence of cancer will drive the product demand in near future. Moreover, to cater increasing disease burden, key market players are adopting developmental activities that will offer unprecedented growth opportunities to the segment in future.
 

Enhanced product availability and accessibility coupled with surge in patient inflow in hospitals will fuel the segment growth potential

Monoclonal antibodies market on the basis of end-use is segmented as hospitals, specialty centers, and others. Hospitals segment was valued around USD 77 billion in 2021 owing to an increase in the number of patient hospitalizations for a range of chronic diseases. Availability of advanced drug therapies in facilities has driven patient preference. Highly skilled professionals providing specialty treatments such as cancer and autoimmune diseases will drive the product demand in hospitals. Moreover, reimbursement policies for high-cost therapies in hospitals will influence patient visits.
 

Presence of key market players catering to large patient pool will stimulate the market demand in North America

Get more details on this report - Request Free Sample PDF
 

North America monoclonal antibodies market held majority of market share that accounted for more than 48% in 2021 owing to the strong presence of key business players and number of product approvals. Enhanced product adoption for effective disease treatment will propel demand for monoclonal antibodies in the regional market. Moreover, increasing R&D expenditure by organizations and support for cancer research by the government has allowed discovery of novel monoclonal antibodies therapeutics.
 

Additionally, expansion of manufacturing capacities will boost product availability and sales. Moreover, increasing number of product approvals in the U.S. and Canada will stimulate the regional market growth. Well-developed healthcare infrastructure has increased treatment accessibility to population, thereby stimulating the product demand. Abovementioned factors are also anticipated to flourish regional monoclonal antibodies market revenue in near future.
 

New product approvals and strategic alliances by established players will offer immense growth opportunities in the market

Some of notable key players operating in the global monoclonal antibodies industry including AbbVie Inc., F. Hoffmann-La Roche, Bristol Myers Squibb, Amgen, Bristol Myers Squibb, Johnson & Johnson, Merck & Co., Inc., Regeneron Pharmaceuticals Inc., AstraZeneca, Eli Lilly and Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, and Novartis AG among others. These market players are adopting numerous growth strategies to strengthen their product portfolio and broaden market footprint.
 

Some of the recent industry developments:

• In June 2021, Amgen entered in agreement with Kyowa Kirin Co. Ltd., to develop and commercialize KHK4083, a fully human monoclonal antibody for the treatment of atopic dermatitis. Such partnerships have helped the company in business expansion.
   
• In May 2021, Roche India announced the Emergency Use Authorisation (EUA) for its antibody cocktail by the Central Drugs Standards Control Organisation (CDSCO). This authorization has enabled the company to broaden product accessibility in the country.
   

The monoclonal antibodies market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2022 to 2028 for the following segments:

By Type

• Fully human
• Humanized
• Chimeric
• Others

By Application

• Oncology
• Autoimmune diseases
• Infectious diseases
• Others

By End-use

• Hospitals
• Specialty centers
• Others

The above information is provided for the following regions and countries:

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Singapore
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Egypt
  • Kuwait